Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2014; 20(45): 17206-17217
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17206
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17206
Table 1 Baseline characteristics of included trials
| Ref. | Country | Design | Treatment | No. pts | Age (yr) | Sex | Tumor size | Tumor number | Child-Pugh class | Virus infection | BCLC stage | ECOG status |
| (M/F) | (cm) | (single/multiple) | (A/B/C) | (HBV/HCV) | (A/B/C/D) | (0/1/2) | ||||||
| Moreno-Luna et al[16] | United States | Clinical study | TARE-90Y | 61 | 64 (29-88) | 49/12 | 5.0 (3.3-8.4) | 13/48 | 53/8/0 | 0/8 | 12/34/15/0 | 51/7/1 |
| (2013) | TACE | 55 | 66 (46-84) | 43/12 | 5.0 (3.2-8.5) | 20/35 | 44/11/0 | 0/7 | 23/13/19/0 | 40/15/0 | ||
| Nicolini et al[21] (2013) | Italy | Clinical study | DEB-TACE | 22 | 57.2 ± 6.5 | 19/3 | 1.8 (0.7-4.5) | 8/14 | NA | 8/10 | 14/8/0/0 | NA |
| TACE | 16 | 55.6 ± 6.5 | 15/1 | 2.2 (1-10) | 8/8 | NA | 3/12 | 7/9/0/0 | NA | |||
| Song et al[12] (2012) | South Korea | Cohort study | DEB-TACE | 60 | 61.7 ± 9.8 | 42/18 | 4.2 ± 2.8 | 26/34 | 56/4/0 | 44/8 | 27/33/0/0 | NA |
| TACE | 69 | 59.0 ± 11.2 | 48/21 | 5.0 ± 3.1 | 31/38 | 62/6/0 | 46/8 | 28/41/0/0 | NA | |||
| Salem et al[17] (2011) | United States | Clinical study | TARE-90Y | 123 | 66 (30-88) | 87/36 | 4.5 (3.1-6.6) | 55/68 | 67/54/2 | 13/42 | 43/65/13/2 | NA |
| TACE | 122 | 61 (33-88) | 102/20 | 3.6 (2.6-5.7) | 57/65 | 67/53/2 | 12/56 | 47/61/12/2 | NA | |||
| van Malenstein et al[13] | Belgium | RCT | DEB-TACE | 16 | 67.3 ± 9.8 | 14/2 | NA | 4/12 | 14/2/0 | 4/4 | 2/9/5/0 | 9/7/0 |
| (2011) | TACE | 14 | 56.6 ± 13.4 | 11/3 | NA | 1/13 | 14/0/0 | 4/0 | 1/10/3/0 | 10/2/2 | ||
| Carr et al[19] (2010) | United States | Cohort study | TARE-90Y | 99 | NA | 70/29 | NA | NA | NA | 9/30 | NA | NA |
| TACE | 691 | NA | 518/173 | NA | NA | NA | 97/132 | NA | NA | |||
| Malagari et al[22] | Greece | RCT | DEB-TACE | 41 | 70.7 ± 6.9 | 31/10 | 8.3 ± 2.7 | 12/29 | 23/18/0 | NA | NA | 26/15/0 |
| (2010) | TACE | 43 | 70.0 ± 7.9 | 34/9 | 8.1 ± 2.8 | 15/28 | 26/17/0 | NA | NA | 28/15/0 | ||
| Dhanasekaran et al[14] | United States | Clinical study | DEB-TACE | 45 | 59.9 ± 11.4 | 35/10 | 5.5 ± 4.3 | 21/24 | 22/11/12 | 5/20 | NA | NA |
| (2010) | TACE | 26 | 58.9 ± 13.3 | 19/7 | 7.4 ± 4.9 | 10/16 | 11/11/4 | 3/11 | NA | NA | ||
| Nicolini et al[20] | Italy | Clinical study | DEB-TACE | 8 | 57.0 ± 3.8 | 8/0 | 3.0 ± 0.9 | 7/1 | 5/3/0 | 0/3 | NA | NA |
| (2010) | TAE | 8 | 56 5 ± 2.0 | 7/1 | 3.4 ± 0.2 | 5/3 | 6/2/0 | 2/4 | NA | NA | ||
| Scartozzi et al[23] | Italy | Clinical study | DEB-TACE | 32 | 68 (41-79) | 29/3 | NA | NA | 14/18/0 | NA | NA | NA |
| (2010) | TACE | 50 | 74 (42-89) | 36/14 | NA | NA | 26/24/0 | NA | NA | NA | ||
| Kooby et al[18] (2010) | United States | Cohort study | TARE-90Y | 27 | 58.7 ± 10.8 | 23/4 | 7.4 ± 3.2 | 12/15 | 13/14/0 | 0/10 | NA | NA |
| TACE | 44 | 61.0 ± 9.9 | 36/8 | 7.4 ± 5.1 | 25/19 | 22/22/0 | 0/25 | NA | NA | |||
| Lewandowski et al[15] | United States | Clinical study | TARE-90Y | 43 | 68 (44-88) | 38/5 | NA | 20/23 | 24/19/0 | NA | 0/34/9/0 | NA |
| (2009) | TACE | 43 | 65 (36-89) | 36/7 | NA | 23/10 | 23/18/2 | NA | 0/37/4/2 | NA | ||
| Ahmad et al[24] (2005) | United States | Clinical study | TARE-90Y | 24 | 61 (40-82) | 20/4 | NA | NA | NA | 5/19 | NA | NA |
| TACE | 52 | 57 (19-80) | 46/6 | NA | NA | NA | 19/28 | NA | NA |
Table 2 Prognosis of patients reported in included trials n (%)
| Ref. | Treatment | No. pts | 1-yr OSR | 2-yr OSR | 3-yr OSR | CR | PR | SD | PD | AFP response | Progression rate1 |
| Moreno-Luna et al[16] | TARE-90Y | 61 | NA | 18 (30) | 13 (21) | 7 (12) | 22 (39) | 22 (39) | 5 (9) | 14 (23) | NA |
| (2013) | TACE | 55 | NA | 13 (24) | 9 (16) | 2 (4) | 22 (47) | 16 (34) | 7 (15) | 18 (33) | NA |
| Nicolini et al[21] | DEB-TACE | 22 | NA | NA | 16 (73.9) | 14 (37) | NA | NA | NA | NA | NA |
| (2010) | TACE | 16 | NA | NA | 9 (58.7) | 7 (28) | NA | NA | NA | NA | NA |
| Song et al[12] (2012) | DEB-TACE | 60 | 53 (88) | NA | NA | 33 (55) | 16 (26) | 9 (15) | 2 (3) | 46 (77) | 30 (50) |
| TACE | 69 | 46 (67) | NA | NA | 16 (23) | 18 (26) | 21 (30) | 14 (20) | 31 (45) | 48 (69) | |
| Salem et al[17] (2011) | TARE-90Y | 123 | 92 (75) | NA | NA | NA | NA | NA | NA | 40 (32) | 42 (34) |
| TACE | 122 | 92 (75) | NA | NA | NA | NA | NA | NA | 37 (30) | 54 (44) | |
| van Malenstein et al[13] | DEB-TACE | 16 | NA | NA | NA | NA | NA | NA | NA | 8 (89) | 3 (23) |
| (2011) | TACE | 14 | NA | NA | NA | NA | NA | NA | NA | 4 (67) | 1 (8) |
| Carr et al[19] (2010) | TARE-90Y | 99 | 50 (50) | NA | NA | 3 (3) | 38 (38) | 35 (35) | 23 (23) | NA | NA |
| TACE | 691 | 301 (43) | NA | NA | 37 (5) | 390 (55) | 199 (29) | 75 (11) | NA | NA | |
| Malagari et al[22] | DEB-TACE | 41 | 35 (85) | NA | NA | 11 (27) | NA | NA | NA | NA | 5 (12) |
| (2010) | TACE | 43 | 37 (86) | NA | NA | 6 (14) | NA | NA | NA | NA | 9 (21) |
| Dhanasekaran et al[14] | DEB-TACE | 45 | 26 (58) | 21 (48) | NA | NA | NA | NA | NA | NA | NA |
| (2010) | TACE | 26 | 8 (31) | 3 (12) | NA | NA | NA | NA | NA | NA | NA |
| Nicolini et al[20] (2013) | DEB-TACE | 8 | NA | NA | NA | 5 (63) | 1 (12) | NA | 2 (25) | NA | NA |
| TACE | 8 | NA | NA | NA | 0 (0) | 5 (63) | NA | 3 (37) | NA | NA | |
| Scartozzi et al[23] (2010) | DEB-TACE | 58 | NA | NA | NA | 14 (24) | 32 (39) | 16 (19) | 19 (22) | NA | NA |
| TACE | 85 | NA | NA | NA | 17 (20) | 19 (33) | 7 (12) | 18 (31) | NA | NA | |
| Kooby et al[18] (2010) | TARE-90Y | 27 | 4 (16) | NA | NA | 0 (0) | 3 (11) | 11 (41) | 9 (33) | 5 (24) | NA |
| TACE | 44 | 9 (20) | NA | NA | 1 (2) | 2 (4) | 16 (36) | 16 (36) | 11 (26) | NA | |
| Lewandowski et al[15] | TARE-90Y | 43 | 33 (77) | 25 (59) | 19 (45) | 20 (47) | 17 (39) | 6 (14) | 0 (0) | NA | 6 (15) |
| (2009) | TACE | 43 | 31 (73) | 12 (28) | 8 (19) | 6 (17) | 19 (54) | 9 (26) | 1 (3) | NA | 11 (32) |
| Ahmad et al[24] (2005) | TARE-90Y | 24 | NA | NA | NA | 22 (92) | NA | NA | NA | NA | NA |
| TACE | 52 | NA | NA | NA | 39 (75) | NA | NA | NA | NA | NA |
-
Citation: Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization
vs microsphere embolization in hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2014; 20(45): 17206-17217 - URL: https://www.wjgnet.com/1007-9327/full/v20/i45/17206.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i45.17206